Business
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors MIAMI, FL / ACCESS Newswire / May 13, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (\"MIRA\" or the \"Company\"), a clinical-stage pharmaceutical company focused on the development of investigational therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and activity of SKNY-1, the Company's oral investigational drug candidate being evaluated for obesity and nicotine addiction, in the International Journal of Molecular Sciences.The publication, titled \"SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity,\" describes in vitro pharmacologic characterization and in vivo preclinical findings observed in an MC4R-deficient zebrafish model exhibiting obesity-associated metabolic and reward-related phenotypes.The full publication is available online through MDPI at International Journal of Molecular Sciences publication.\"Despite significant advances in obesity treatment, existing therapeutic approaches continue to face limitations related to tolerability, long-term adherence, durability of response, and increasing clinical focus on preservation of lean body mass during weight reduction,\" said Erez Aminov, CEO of MIRA. \"We believe the publication of these peer-reviewed findings further supports the differentiated pharmacological profile of SKNY-1 and its potential as a novel oral investigational approach targeting both metabolic and reward-associated pathways.\"According to the publication, SKNY-1 demonstrated differential engagement of cannabinoid receptor 1 (CB1) signaling pathways, partial agonist activity at cannabinoid receptor 2 (CB2), and selective in vitro inhibition of monoamine oxidase B (MAO-B) relative to MAO-A. The manuscript further reports that oral administration of SKNY-1 in the mc4r(G894C) zebrafish model was associated with dose-dependent reductions in body weight, modulation of lipid parameters, reduction of hepatic triglyceride accumulation, and attenuation of compulsive feeding and nicotine-seeking behavi...